|
|||||
|
|

Senior living provider Brookdale Senior Living (NYSE:BKD) missed Wall Street’s revenue expectations in Q4 CY2025, with sales falling 3.4% year on year to $754.1 million. Its non-GAAP loss of $0.14 per share was 17.5% above analysts’ consensus estimates.
Is now the time to buy BKD? Find out in our full research report (it’s free for active Edge members).
Brookdale’s fourth-quarter results were met with a significant negative market reaction, reflecting concerns over the company’s revenue decline and execution against Wall Street’s expectations. Management attributed the underperformance primarily to a sharp reduction in the number of communities following a series of lease terminations and asset dispositions, which outpaced growth in occupancy and pricing. CEO Nikolas Stengle pointed to “steady improvement in occupancy and margin expansion” as bright spots, but acknowledged that these gains could not fully offset the impact of ongoing portfolio optimization and lower average unit counts during the period.
Looking ahead, Brookdale’s leadership is focused on leveraging demographic tailwinds and internal operational changes to drive sustained adjusted EBITDA and occupancy growth. Management highlighted plans to accelerate reinvestment in select communities, implement a more centralized pricing strategy, and expand the Health Plus care coordination platform. In discussing 2026 expectations, CFO Dawn L. Kussow cited “mid-to-high single digit in-place rate increases and robust move-in demand” as key assumptions behind the company’s outlook for revenue per available room, while cautioning that effective execution on targeted capital projects and ongoing labor cost control will be critical to achieving guidance.
Management emphasized that portfolio streamlining, occupancy gains, and organizational restructuring shaped both recent performance and the outlook for the coming year.
Management’s outlook for the next year is anchored by demographic-driven demand, targeted portfolio improvements, and disciplined rate increases offset by ongoing cost pressures.
Looking forward, the StockStory team will be watching (1) execution of the remaining asset dispositions and their impact on overall occupancy and margin metrics, (2) the results of targeted capital investments in select communities as measured by improvements in net operating income and resident retention, and (3) further expansion of the Health Plus platform and its contribution to length of stay and move-in rates. Progress on labor cost containment and the effects of the new regional structure will also be key indicators of success.
Brookdale currently trades at $15.53, down from $16.56 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).
Your portfolio can’t afford to be based on yesterday’s story. The risk in a handful of heavily crowded stocks is rising daily.
The names generating the next wave of massive growth are right here in our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
| Mar-10 | |
| Mar-09 | |
| Mar-06 | |
| Mar-03 | |
| Mar-02 | |
| Feb-26 | |
| Feb-25 | |
| Feb-24 | |
| Feb-24 | |
| Feb-20 | |
| Feb-19 | |
| Feb-19 | |
| Feb-19 | |
| Feb-19 | |
| Feb-19 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about Finviz Elite